PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP
Status:
Terminated
Trial end date:
2018-05-17
Target enrollment:
Participant gender:
Summary
Pre-clinical and clinical evaluations show that PRTX- 100 has biological activity that may
lead to improved platelet levels where these are decreased due to immunological pathologies
and that PRTX-100 has an acceptable safety profile. In vivo treatment with PRTX-100 has been
shown to raise platelet counts in a mouse model of immune thrombocytopenia (ITP). The primary
objective of the study is to assess the efficacy of PRTX-100 in terms of platelet response in
patients with chronic/persistent ITP.